Latest News for: igg4
Edit
IgG4-related disease Market Outlook 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Revenue, Statistics, Therapies, Prevalence, ...
GetNews 26 Aug 2025
Edit
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Nasdaq Globe Newswire 14 Aug 2025
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease ... .
Edit
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease (Sanofi SA)
Public Technologies 14 Aug 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 125943169) .
Edit
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Pharmiweb 14 Aug 2025
The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD) ... About IgG4-RD.
Edit
IgG4-Related Disease Pipeline Insight 2025: Advancing Targeted Immunotherapy to Address Fibroinflammatory Burden | DelveInsight
GetNews 21 Jul 2025
Edit
Media Update: EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US (Sanofi SA)
Public Technologies 12 Jun 2025
New data from a phase 2 study showed that treatment with rilzabrutinib led to a considerable reduction in disease flares and other key disease markers, as well as glucocorticoid (GC) sparing, in patients with active IgG4-related disease (IgG4-RD).
- 1